Literature DB >> 17698150

The protective effect of ApolipoproteinA-I on myocardial ischemia-reperfusion injury in rats.

Shan-Shan Gu1, Ning Shi, Man-Ping Wu.   

Abstract

It is well established that reperfusion of heart is the optimal method for salvaging ischemic myocardium, however, the success of this therapy could be limited by reperfusion injury, which is involved in inflammatory responses. High density lipoprotein (HDL) has an anti-inflammatory function and can protect the heart from ischemia-reperfusion (I/R) injury. In this study, we investigated the cardioprotective role of apolipoprotein A-I (ApoA-I), the major apolipoprotein of HDL, in I/R injury. Using rats subjected to myocardial I/R by ligation of left anterior descending coronary artery (LAD), we found that administration of ApoA-I (20 mg/kg, iv) before the onset of reperfusion of myocardial infarction can significantly reduce serum creatine kinase (CK) levels (62.1+/-13.8%, p<0.01) and heart TNF-alpha as well as IL-6 levels, compared with saline controls (40.4+/-14.7%, 44+/-9.8%, p<0.01 respectively). Moreover, ApoA-I treatment suppresses the expression of ICAM-1 on endothelium, thus diminishing neutrophil adherence, transendothelial migration, and the subsequent myocyte injury. We concluded that ApoA-I could effectively protect rat heart from I/R injury.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17698150     DOI: 10.1016/j.lfs.2007.06.021

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  8 in total

Review 1.  Hyperlipidaemia and cardioprotection: Animal models for translational studies.

Authors:  Ioanna Andreadou; Rainer Schulz; Lina Badimon; Adriana Adameová; Petra Kleinbongard; Sandrine Lecour; Panagiota-Efstathia Nikolaou; Ines Falcão-Pires; Gemma Vilahur; Nicholas Woudberg; Gerd Heusch; Péter Ferdinandy
Journal:  Br J Pharmacol       Date:  2020-01-17       Impact factor: 8.739

Review 2.  High density lipoprotein/sphingosine-1-phosphate-induced cardioprotection: Role of STAT3 as part of the SAFE pathway.

Authors:  Miguel A Frias; Sandrine Lecour; Richard W James; Sarah Pedretti
Journal:  JAKSTAT       Date:  2012-04-01

3.  Apolipoprotein a-I is a potential mediator of remote ischemic preconditioning.

Authors:  Pierre Hibert; Delphine Prunier-Mirebeau; Olivia Beseme; Maggy Chwastyniak; Sophie Tamareille; Delphine Lamon; Alain Furber; Florence Pinet; Fabrice Prunier
Journal:  PLoS One       Date:  2013-10-14       Impact factor: 3.240

4.  RISK and SAFE signaling pathway involvement in apolipoprotein A-I-induced cardioprotection.

Authors:  Hussein Kalakech; Pierre Hibert; Delphine Prunier-Mirebeau; Sophie Tamareille; Franck Letournel; Laurent Macchi; Florence Pinet; Alain Furber; Fabrice Prunier
Journal:  PLoS One       Date:  2014-09-19       Impact factor: 3.240

5.  High Density Lipoprotein Reduces Blood Pressure and Protects Spontaneously Hypertensive Rats Against Myocardial Ischemia-Reperfusion Injury in an SR-BI Dependent Manner.

Authors:  Aishah Al-Jarallah; Fawzi Babiker
Journal:  Front Cardiovasc Med       Date:  2022-03-21

6.  Remote ischemic preconditioning (RIPC) modifies plasma proteome in humans.

Authors:  Michele Hepponstall; Vera Ignjatovic; Steve Binos; Paul Monagle; Bryn Jones; Michael H H Cheung; Yves d'Udekem; Igor E Konstantinov
Journal:  PLoS One       Date:  2012-11-05       Impact factor: 3.240

7.  Telmisartan protects against microvascular dysfunction during myocardial ischemia/reperfusion injury by activation of peroxisome proliferator-activated receptor γ.

Authors:  Xiao-Cong Zeng; Xing-San Li; Hong Wen
Journal:  BMC Cardiovasc Disord       Date:  2013-06-05       Impact factor: 2.298

Review 8.  Current Understanding of the Immunomodulatory Activities of High-Density Lipoproteins.

Authors:  Athina Trakaki; Gunther Marsche
Journal:  Biomedicines       Date:  2021-05-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.